January 30, 2024 08:49 AM EST
Cell/Gene Tx
Manufacturing

Gilead, Kite short­en Yescar­ta man­u­fac­tur­ing by two days in 'in­cre­men­tal' im­prove­ment

Max Gelman

Senior Editor

Gilead and Kite an­nounced Tues­day it re­ceived FDA ap­proval to short­en its man­u­fac­tur­ing process for the cell ther­a­py Yescar­ta, a move …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times